Celyad Oncology Past Earnings Performance
Past criteria checks 0/6
Celyad Oncology has been growing earnings at an average annual rate of 7.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 93.5% per year.
Key information
7.1%
Earnings growth rate
24.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -93.5% |
| Return on equity | -134.0% |
| Net Margin | -8,282.4% |
| Next Earnings Update | 06 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Celyad Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 6 | 4 |
| 30 Sep 23 | 0 | -20 | 7 | 7 |
| 30 Jun 23 | 0 | -31 | 8 | 11 |
| 31 Mar 23 | 0 | -35 | 10 | 15 |
| 31 Dec 22 | 0 | -41 | 11 | 19 |
| 30 Sep 22 | 0 | -32 | 11 | 20 |
| 30 Jun 22 | 0 | -26 | 11 | 21 |
| 31 Mar 22 | 0 | -25 | 10 | 21 |
| 31 Dec 21 | 0 | -27 | 10 | 21 |
| 30 Sep 21 | 0 | -17 | 9 | 21 |
| 30 Jun 21 | 0 | -15 | 9 | 20 |
| 31 Mar 21 | 0 | -18 | 9 | 21 |
| 31 Dec 20 | 0 | -17 | 9 | 21 |
| 30 Sep 20 | 0 | -28 | 10 | 22 |
| 30 Jun 20 | 0 | -29 | 9 | 24 |
| 31 Mar 20 | 0 | -29 | 9 | 24 |
| 31 Dec 19 | 0 | -29 | 9 | 25 |
| 30 Sep 19 | 0 | -32 | 9 | 25 |
| 30 Jun 19 | 1 | -35 | 9 | 25 |
| 31 Mar 19 | 2 | -36 | 10 | 24 |
| 31 Dec 18 | 3 | -37 | 10 | 24 |
| 30 Sep 18 | 3 | -49 | 10 | 23 |
| 30 Jun 18 | 3 | -60 | 11 | 23 |
| 31 Mar 18 | 3 | -58 | 10 | 23 |
| 31 Dec 17 | 4 | -56 | 9 | 23 |
| 30 Sep 17 | 9 | -39 | 9 | 23 |
| 30 Jun 17 | 12 | -21 | 9 | 23 |
| 31 Mar 17 | 10 | -22 | 9 | 26 |
| 31 Dec 16 | 10 | -24 | 10 | 28 |
| 30 Sep 16 | 4 | -27 | 9 | 27 |
| 30 Jun 16 | 0 | -31 | 8 | 27 |
| 31 Mar 16 | 0 | -30 | 8 | 25 |
| 31 Dec 15 | 0 | -29 | 7 | 23 |
| 30 Sep 15 | 0 | -27 | 7 | 22 |
| 30 Jun 15 | 0 | -25 | 7 | 21 |
| 31 Mar 15 | 0 | -21 | 6 | 18 |
| 31 Dec 14 | 0 | -16 | 5 | 16 |
| 30 Sep 14 | 0 | -15 | 5 | 15 |
| 30 Jun 14 | 0 | -14 | 5 | 14 |
| 31 Mar 14 | 0 | -15 | 5 | 12 |
| 31 Dec 13 | 0 | -14 | 4 | 9 |
| 30 Sep 13 | 0 | -14 | 3 | 6 |
| 30 Jun 13 | 0 | -13 | 2 | 2 |
Quality Earnings: 0QFK is currently unprofitable.
Growing Profit Margin: 0QFK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0QFK is unprofitable, but has reduced losses over the past 5 years at a rate of 7.1% per year.
Accelerating Growth: Unable to compare 0QFK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0QFK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: 0QFK has a negative Return on Equity (-134.01%), as it is currently unprofitable.